🇺🇸 FDA
Patent

US 12391750

Anti-C1S antibodies and methods of use thereof

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 12391750 (Anti-C1S antibodies and methods of use thereof) held by Bioverativ USA Inc. expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bioverativ USA Inc.
Grant date
Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K38/00, A61K45/06, A61P